Neurology

Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder



Objective

To assess the dose-response of daridorexant, a new dual orexin receptor antagonist, on wake after sleep onset (WASO).

Methods

Elderly (≥65 years) participants (n = 58) with insomnia were randomly allocated (Latin square design) to receive 5 treatments (5, 10, 25, and 50 mg daridorexant and placebo) during 5 treatment periods, each consisting of 2 treatment nights followed by a 5- to 12-day washout period. Main efficacy endpoints were the absolute change from baseline in WASO (primary) and latency to persistent sleep (LPS; secondary) to days 1 and 2 (mean of 2 treatment nights assessed by polysomnography) in each period. Safety and tolerability were also assessed.

Results

Of 58 participants included, 67% were female, and the median age was 69 years (range 65–85 years). WASO and LPS were dose-dependently reduced from baseline to days 1 and 2 after daridorexant administration (multiple comparison procedure modeling, p < 0.0001 and p = 0.004, respectively); reductions were statistically significant for doses ≥10 mg compared with placebo (WASO: –32.0, –45.1, –61.4 minutes; LPS: –44.9, –43.8, –45.4 minutes for 10, 25, and 50 mg, respectively, p ≤ 0.025). Treatment-emergent adverse events were similar for daridorexant and placebo; the most frequent were fatigue, nasopharyngitis, gait disturbance, and headache (≤7% in any group).

Conclusions

Daridorexant was well tolerated. Dose-dependent improvements in WASO and LPS were statistically significant (dose range 10–50 mg) in elderly people with insomnia disorder.

ClinicalTrials.gov identifier:

NCT02841709.

Classification of evidence

This study provides Class I evidence that, for elderly people with insomnia, daridorexant reduced WASO.

Source link

Related posts

Predicting Abnormal Neurodevelopment in Zika-Exposed Infants

Newsemia

Sleep Complaints, Sleep and Breathing Disorders in Myotonic Dystrophy Type 2.

Newsemia

Why are neuron axons long and spindly? Study shows they're optimizing signaling efficiency

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World